Dr. Tycel J. Phillips, M.D.
Hematology (Hematology (Internal Medicine) Physician)
1500 Duarte Rd
Duarte, CA 91010
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 128
Licensed in California since 2022, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
CA license C178254 (first issued 2022; current) · MI license 4301101826 -
Hematology & Oncology Physician
MI license 4301101826 -
Internal Medicine Physician
MI license 4301101826 -
Medical Oncology Physician
CA license C178254 (first issued 2022; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- City of Hope Medical Foundation (982 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 128
- Services billed
- 572
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 214 | 44 |
| Established patient office or other outpatient visit, 40-54 minutes | 145 | 39 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 18 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brukinsa (zanubrutinib) | 38 |
| Revlimid (lenalidomide) | 29 |
| Acyclovir Other prescribers in Duarte, CA | 28 |
| Prednisone Other prescribers in Duarte, CA | 21 |
| Dexamethasone Other prescribers in Duarte, CA | 16 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Duarte, CA | 14 |
| Allopurinol Other prescribers in Duarte, CA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 54 payments worth $52,132 in total to this clinician.
| Genentech USA, Inc. | $10,548 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $10,311 |
| AstraZeneca Pharmaceuticals LP | $8,760 |
| Beone Medicines USA, Inc. | $5,780 |
| Pfizer Inc. | $4,253 |
| Roche Products Limited | $3,470 |
| Incyte Corporation | $2,486 |
| AbbVie Inc. | $1,699 |
| Consulting Fee | $48,281 |
|---|---|
| Food and Beverage | $1,826 |
| Speaking at a medical education program | $1,000 |
| Travel and Lodging | $792 |
| Compensation for services other than consulting (speaking, faculty) | $233 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jan 7, 2025 | Consulting Fee CALQUENCE · Oncology Company’s descriptionResearch Related Service | $5,480 |
| E.r. Squibb & Sons, L.l.c. Feb 18, 2025 | Consulting Fee | $4,844 |
| E.r. Squibb & Sons, L.l.c. Aug 14, 2025 | Consulting Fee | $4,775 |
| Genentech USA, Inc. Dec 4, 2025 | Consulting Fee Polivy · BioOncology | $4,100 |
| Beone Medicines USA, Inc. Oct 21, 2025 | Consulting Fee | $4,000 |
| Pfizer Inc. Nov 7, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $3,300 |
| AstraZeneca Pharmaceuticals LP Jan 16, 2025 | Consulting Fee CALQUENCE · Oncology | $3,280 |
| Genentech USA, Inc. Jul 28, 2025 | Consulting Fee Polivy; Columvi; Lunsumio · BioOncology | $2,870 |
| Genentech USA, Inc. Apr 30, 2025 | Consulting Fee Columvi · BioOncology | $2,460 |
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $2,398 |
All 28 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $2,398 |
| Genmab U.S., Inc. Dec 18, 2025 | Consulting Fee Epkinly · Oncology | $1,178 |
| Beone Medicines USA, Inc. Dec 11, 2025 | Consulting Fee | $1,600 |
| Pfizer Inc. Dec 8, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $720 |
| Roche Products Limited Dec 5, 2025 | Consulting Fee | $1,520 |
| Genentech USA, Inc. Dec 4, 2025 | Consulting Fee Polivy · BioOncology | $4,100 |
| Genentech USA, Inc. Dec 4, 2025 | Travel and Lodging Polivy · BioOncology · travel to Orlando, FL · in-kind | $298 |
| Genentech USA, Inc. Dec 4, 2025 | Travel and Lodging Polivy · BioOncology · travel to Orlando, FL · in-kind | $196 |
| Genentech USA, Inc. Dec 4, 2025 | Travel and Lodging Polivy · BioOncology · travel to Orlando, FL | $99.63 |
| Pfizer Inc. Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) ADCETRIS · ONCOLOGY | $233 |
| Pfizer Inc. Nov 7, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $3,300 |
| Beone Medicines USA, Inc. Oct 21, 2025 | Consulting Fee | $4,000 |
| Janssen Global Services, LLC Sep 12, 2025 | Consulting Fee | $1,410 |
| Merck Sharp & Dohme LLC Aug 20, 2025 | Consulting Fee IMMUNOLOGY Company’s descriptionProvided as part of a research engagement. | $305 |
| E.r. Squibb & Sons, L.l.c. Aug 14, 2025 | Consulting Fee | $4,775 |
| Genentech USA, Inc. Jul 28, 2025 | Consulting Fee Polivy; Columvi; Lunsumio · BioOncology | $2,870 |
| AbbVie Inc. Jul 14, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $300 |
| Roche Products Limited May 19, 2025 | Consulting Fee | $1,900 |
| Genentech USA, Inc. Apr 30, 2025 | Consulting Fee Columvi · BioOncology | $2,460 |
| Genentech USA, Inc. Apr 30, 2025 | Travel and Lodging Columvi · BioOncology · travel to Chicago, IL · in-kind | $198 |
| AbbVie Inc. Apr 15, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $300 |
| E.r. Squibb & Sons, L.l.c. Feb 18, 2025 | Consulting Fee | $4,844 |
| Celgene Corporation Feb 14, 2025 | Speaking at a medical education program | $1,000 |
| AbbVie Inc. Feb 5, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $300 |
| AbbVie Inc. Jan 23, 2025 | Consulting Fee | $550 |
| E.r. Squibb & Sons, L.l.c. Jan 21, 2025 | Consulting Fee | $692 |
| AstraZeneca Pharmaceuticals LP Jan 16, 2025 | Consulting Fee CALQUENCE · Oncology | $3,280 |
| AstraZeneca Pharmaceuticals LP Jan 7, 2025 | Consulting Fee CALQUENCE · Oncology Company’s descriptionResearch Related Service | $5,480 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 4 companies. The companies reported $4,124,944 in research payments for these studies, mostly to the institutions running them.
- A16-425;Venclexta;Bottle: ABT-199 100mg Yellow Film Coated Tablet 120 Tablets
AbbVie Inc. - Phase I multi-site study evaluating the MTD, safety and efficacy of the combination venetoclax, lenalidomide and rituximab in patients with previously untreated mantle cell lymphoma
AbbVie Inc. - Ph 3 study in patients with Mantle Cell Lymphoma treated with glofitmab vs R chemo or R Len
Genentech, Inc. - Phase I multi-site study evaluating the MTD safety and efficacy of the combination venetoclax lenalidomide and rituximab in patients with previously untreated mantle cell lymphoma
AbbVie Inc. - Glofit w ven len in MCL
Genentech, Inc. - A Pilot Study of Pacritinib Combined with a BTK inhibitor in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Sobi, Inc - A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
Beone Medicines Ltd. · Active, not recruiting · NCT04170283 - A16-425;Venclexta;Blister Card: ABT-199 100mg Film-coated Tablet 2x8, 16 Tablets
AbbVie Inc. - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
AbbVie Inc. · Active, not recruiting · NCT06508658
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.